Renal Cell Carcinoma: Advances Across the Treatment Continuum

---

ONLINERenal Cell

Tuesday, August 25, 2020, 12:00 AM - Wednesday, August 25, 2021, 11:59 PM


AMA PRA Category 1 Credits™ (2.00 hours), Non-Physician Attendance (2.00 hours)

Clinical Advances in the Landscape of Renal Cell Carcinoma (RCC): Role of Immunotherapies in Treatment is a 2 hour internet enduring material designed for medical oncologists and the multidisciplinary care team with the purpose of sharing recent data on approved and emerging immunotherapies to improve treatment of renal cell carcinoma (RCC).

1. Compare and contrast evidence from immunotherapy clinical trials to assess how newly approved and emerging immunotherapies improve treatment of RCC, including combination anti-VEGF and immunotherapeutic platforms
2. Discuss clinical factors when immunotherapy or combination immunotherapy should be considered as a treatment option for patients with RCC, such as patient selection, optimal drug combinations, and treatment sequence
3. Review clinical strategies for the early detection and management of immunotherapy and immunotherapy combination related adverse events in RCC patients and management plans to help mitigate them

View the accessibility policy for The University of Texas M.D Anderson Cancer Center.

 

The University of Texas MD Anderson Cancer Center complies with all requirements of the identified accrediting body  (ACCME, ANCC, ACPE). Disclosure of speakers, faculty members, planning committee members and their commercial relationships will be shared with learners prior to the educational activity.

Supported by an educational grant from Pfizer and EMD Serono.